Eagle Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2015 Results

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/24/2026

1. DECK
2. RNG
3. WDC
4. BYD
5. SPOT
6. WCN
7. BMY
8. TSCO
9. BE
10. SPY

Go back to Eagle Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2015 Results

Mizuho Securities Remains Bullish on Eagle Pharmaceuticals (EGRX) Despite Weak 4Q; Investors Focus on Bendeka Opportunity

February 26, 2016 7:04 AM EST

Mizuho Securities maintained a Buy rating on Eagle Pharmaceuticals (NASDAQ: EGRX), and cut the price target to $81.00 (from $112.00), following the company's 4Q earnings report. EGRX reported 4Q revenues of $18.2M and EPS of $0.07, missing the consensus estimates of $20.8M and $0.30. The most... More

Eagle Pharmaceuticals (EGRX) Misses Q4 EPS Views

February 25, 2016 6:50 AM EST

Eagle Pharmaceuticals (NASDAQ: EGRX) reported Q4 EPS of $0.07, $0.23 worse than the analyst estimate of $0.30. Revenue for the quarter came in at $18.2 million versus the consensus estimate of $20.78 million.

For earnings history and earnings-related data on Eagle Pharmaceuticals (EGRX) click here.

... More